Incannex Healthcare Limited (IXHL)
NASDAQ: IXHL · IEX Real-Time Price · USD
2.310
-0.080 (-3.35%)
At close: May 6, 2024, 4:00 PM
2.260
-0.050 (-2.16%)
After-hours: May 6, 2024, 4:17 PM EDT
Incannex Healthcare Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
36.66M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 0 | - | - |
| Jun 30, 2022 | 0 | - | - |
| Jun 30, 2021 | 1.97M | 1.15M | 140.05% |
| Jun 30, 2020 | 822.05K | - | - |
| Jun 30, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Owlet | 54.01M |
| CASI Pharmaceuticals | 33.88M |
| Rapid Micro Biosystems | 22.52M |
| ImmuCell | 17.47M |
| electroCore | 16.03M |
| Co-Diagnostics | 6.81M |
| Marker Therapeutics | 3.31M |
| SAB Biotherapeutics | 2.24M |
IXHL News
- 5 days ago - Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) - Newsfile Corp
- 2 months ago - Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation - GlobeNewsWire
- 3 months ago - Clarion Clinics Open for Psychedelic-Assisted Treatments - GlobeNewsWire
- 3 months ago - Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis - GlobeNewsWire
- 3 months ago - Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences - GlobeNewsWire
- 3 months ago - Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - GlobeNewsWire
- 4 months ago - Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia - GlobeNewsWire
- 5 months ago - Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea - GlobeNewsWire